Bluejay Diagnostics: reports baseline clinical characteristics from SYMON-II

What happened On Oct 6, 2026, Bluejay Diagnostics, Inc. issued a press release regarding baseline clinical characteristics from its SYMON-II clinical validation study, as reported in a Form 8-K filed the same day. The filing lists the disclosure under Regulation FD.

Key details

• The disclosure was made on Oct 6, 2026, and was reported under Item 7.01 (Regulation FD Disclosure).
• The subject of the press release is baseline clinical characteristics from the SYMON-II clinical validation study.
• The Form 8-K states the company issued a press release conveying this information.

Why it may matter This Form 8-K reports Item 7.01, Regulation FD Disclosure, which covers public disclosure of material information and in this case attaches a press release about SYMON-II baseline clinical characteristics. The filing does not show why the insider traded or why the company acted.